Lushang Freda Pharmaceutical Co (SHSE:600223) Risk Assessment

View and export this data going back to 2000. Start your Free Trial

What is Lushang Freda Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Lushang Freda Pharmaceutical Co is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Lushang Freda Pharmaceutical Co's Risk Assessment

For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lushang Freda Pharmaceutical Co's Risk Assessment Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Lushang Freda Pharmaceutical Co's Risk Assessment falls into.

Lushang Freda Pharmaceutical Co (SHSE:600223) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Lushang Freda Pharmaceutical Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Lushang Freda Pharmaceutical Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Lushang Freda Pharmaceutical Co (SHSE:600223) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Lushang Freda Pharmaceutical Co Ltd (SHSE:600223) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN

Website

http://www.lshzy.com.cn

Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.

Executives

Li Hang	senior management
Yin Wei	Directors, senior managers
Shao Zhao Wei	senior management
Wang Zhong Wu	senior management
Dong Hong Lin	Director
Zhou Hong Bo	senior management
Li Lu	senior management
Liu Zeng Wei	senior management
Zhang Quan Li	senior management
Xu Tao	senior management
Ju Hai Bo	Director
Zhao Xi Liang	Director
Pi Xi Cai	Supervisors

Lushang Freda Pharmaceutical Co (SHSE:600223) Headlines

No Headlines